Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes

Authors: Peng Liu, Bai-Lu Xie, Shao-Hui Cai, Yun-Wen He, Ge Zhang, Yan-Mei Yi, Jun Du

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Tumor-specific cytotoxic T cells and infiltrating lymphocytes are frequently found in tumor tissues in patients with nasopharyngeal carcinoma (NPC). Most patients with NPC, however, especially those with advanced stages, have a poor clinical prognosis despite conventional immunotherapy. The aim of this work was to examine the effect of indoleamine 2,3-dioxygenase (IDO), an immunosuppressive enzyme, on the lymphocyte function in NPC.

Methods

The NPC cell line CNE2 was treated by interferon-γ (IFNγ) and the levels of IDO expression was analyzed by Western blotting and reverse phase high-performance liquid chromatography (HPLC). Lymphocytes from health human exposed to the milieu created by IDO-positive CNE2 cells and the lymphocyte cytotoxicity to target tumor cells was analyzed by standard lactate dehydrogenase (LDH) release assay. Additionally, expression of IDO was determined by Immunohistochemical assay in the tumor tissues form clinically evaluated NPC.

Results

IDO expression was acutely induced in the NPC cell line CNE2 by low dose interferon-γ (IFNγ) or by co-incubation with activated lymphocytes. Exposure to the milieu created by IDO-positive CNE2 cells did not promote lymphocyte death, but lymphocyte cytotoxicity against target tumor cells was impaired. The suppression of lymphocyte cytotoxic function was fully restored when the conditioned medium was replaced by fresh medium for 24 h. In additionally, the IDO-positive cells were found scattered in the tumor tissues from patients with NPC.

Conclusion

Altogether, these findings suggest that IDO-mediated immunosuppression may be involved in the tumor immune evasion, and that blocking IDO activity in tumor cells may help to re-establish an effective anti-tumor T cell response in NPC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP: Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003, 39 (15): 2121-2135. 10.1016/S0959-8049(03)00367-8.CrossRefPubMed Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP: Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003, 39 (15): 2121-2135. 10.1016/S0959-8049(03)00367-8.CrossRefPubMed
2.
go back to reference Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365 (9476): 2041-2054. 10.1016/S0140-6736(05)66698-6.CrossRefPubMed Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365 (9476): 2041-2054. 10.1016/S0140-6736(05)66698-6.CrossRefPubMed
3.
go back to reference Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, et al: Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009, 113 (11): 2442-2450. 10.1182/blood-2008-05-157222.CrossRefPubMedPubMedCentral Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, et al: Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009, 113 (11): 2442-2450. 10.1182/blood-2008-05-157222.CrossRefPubMedPubMedCentral
4.
go back to reference Williams CA, Harry RA, McLeod JD: Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology. 2008, 124 (1): 89-101. 10.1111/j.1365-2567.2007.02743.x.CrossRefPubMedPubMedCentral Williams CA, Harry RA, McLeod JD: Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology. 2008, 124 (1): 89-101. 10.1111/j.1365-2567.2007.02743.x.CrossRefPubMedPubMedCentral
5.
go back to reference Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 1997, 15: 749-795. 10.1146/annurev.immunol.15.1.749.CrossRefPubMed Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 1997, 15: 749-795. 10.1146/annurev.immunol.15.1.749.CrossRefPubMed
6.
go back to reference Zanetti F, Elies S: Treatment of nasopharyngeal cancer with recombinant gamma interferon (IFN). A report based on 2 patients. Laryngol Rhinol Otol (Stuttg). 1987, 66 (1): 54-56. 10.1055/s-2007-998597.CrossRef Zanetti F, Elies S: Treatment of nasopharyngeal cancer with recombinant gamma interferon (IFN). A report based on 2 patients. Laryngol Rhinol Otol (Stuttg). 1987, 66 (1): 54-56. 10.1055/s-2007-998597.CrossRef
7.
go back to reference Mahjoubi R, Bachouchi M, Munck JN, Busson P, Gasmi J, Azli N, Brandely M, Trusz T, Cvitkovic E, Armand JP: Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head & neck. 1993, 15 (2): 115-118. 10.1002/hed.2880150206.CrossRef Mahjoubi R, Bachouchi M, Munck JN, Busson P, Gasmi J, Azli N, Brandely M, Trusz T, Cvitkovic E, Armand JP: Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head & neck. 1993, 15 (2): 115-118. 10.1002/hed.2880150206.CrossRef
8.
go back to reference Dimery IW, Jacobs C, Tseng A, Saks S, Pearson G, Hong WK, Gutterman JU: Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma. J Biol Response Mod. 1989, 8 (3): 221-226.PubMed Dimery IW, Jacobs C, Tseng A, Saks S, Pearson G, Hong WK, Gutterman JU: Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma. J Biol Response Mod. 1989, 8 (3): 221-226.PubMed
9.
go back to reference Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Eynde Van den BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat med. 2003, 9 (10): 1269-1274. 10.1038/nm934.CrossRefPubMed Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Eynde Van den BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat med. 2003, 9 (10): 1269-1274. 10.1038/nm934.CrossRefPubMed
10.
go back to reference Grohmann U, Fallarino F, Puccetti P: DCs and tryptophan: much ado about IDO. Trends immunol. 2003, 24 (5): 242-248. 10.1016/S1471-4906(03)00072-3.CrossRefPubMed Grohmann U, Fallarino F, Puccetti P: DCs and tryptophan: much ado about IDO. Trends immunol. 2003, 24 (5): 242-248. 10.1016/S1471-4906(03)00072-3.CrossRefPubMed
11.
go back to reference Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P: T cell apoptosis by tryptophan catabolism. Cell death differ. 2002, 9 (10): 1069-1077. 10.1038/sj.cdd.4401073.CrossRefPubMed Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P: T cell apoptosis by tryptophan catabolism. Cell death differ. 2002, 9 (10): 1069-1077. 10.1038/sj.cdd.4401073.CrossRefPubMed
12.
go back to reference Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004, 4 (10): 762-774. 10.1038/nri1457.CrossRefPubMed Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004, 4 (10): 762-774. 10.1038/nri1457.CrossRefPubMed
13.
go back to reference Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J exp med. 1999, 189 (9): 1363-1372. 10.1084/jem.189.9.1363.CrossRefPubMedPubMedCentral Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J exp med. 1999, 189 (9): 1363-1372. 10.1084/jem.189.9.1363.CrossRefPubMedPubMedCentral
14.
go back to reference Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, et al: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006, 12 (4): 1144-1151. 10.1158/1078-0432.CCR-05-1966.CrossRefPubMed Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, et al: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006, 12 (4): 1144-1151. 10.1158/1078-0432.CCR-05-1966.CrossRefPubMed
15.
go back to reference Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S: Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer sci. 2007, 98 (6): 874-881. 10.1111/j.1349-7006.2007.00470.x.CrossRefPubMed Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S: Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer sci. 2007, 98 (6): 874-881. 10.1111/j.1349-7006.2007.00470.x.CrossRefPubMed
16.
go back to reference Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, et al: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005, 11 (16): 6030-6039. 10.1158/1078-0432.CCR-04-2671.CrossRefPubMed Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, et al: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005, 11 (16): 6030-6039. 10.1158/1078-0432.CCR-04-2671.CrossRefPubMed
17.
go back to reference Zeng J, Cai S, Yi Y, He Y, Wang Z, Jiang G, Li X, Du J: Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan. Cancer res. 2009, 69 (9): 3963-3970. 10.1158/0008-5472.CAN-08-2476.CrossRefPubMed Zeng J, Cai S, Yi Y, He Y, Wang Z, Jiang G, Li X, Du J: Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan. Cancer res. 2009, 69 (9): 3963-3970. 10.1158/0008-5472.CAN-08-2476.CrossRefPubMed
18.
go back to reference Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006, 95 (11): 1555-1561. 10.1038/sj.bjc.6603477.CrossRefPubMedPubMedCentral Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006, 95 (11): 1555-1561. 10.1038/sj.bjc.6603477.CrossRefPubMedPubMedCentral
19.
go back to reference He Y, Cai S, Zhang G, Li X, Pan L, Du J: Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. Virus res. 2008, 135 (1): 175-180. 10.1016/j.virusres.2008.03.012.CrossRefPubMed He Y, Cai S, Zhang G, Li X, Pan L, Du J: Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. Virus res. 2008, 135 (1): 175-180. 10.1016/j.virusres.2008.03.012.CrossRefPubMed
20.
go back to reference Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer lett. 2001, 169 (1): 27-32. 10.1016/S0304-3835(01)00547-X.CrossRefPubMed Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer lett. 2001, 169 (1): 27-32. 10.1016/S0304-3835(01)00547-X.CrossRefPubMed
21.
go back to reference Xie BL, Liu P, Ou XL, Du J: Preparation of anti-human indoleamine 2,3-dioxygenase polyclonal antibody. Ai Zheng. 2007, 26 (3): 329-332.PubMed Xie BL, Liu P, Ou XL, Du J: Preparation of anti-human indoleamine 2,3-dioxygenase polyclonal antibody. Ai Zheng. 2007, 26 (3): 329-332.PubMed
22.
go back to reference Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000, 164 (7): 3596-3599.CrossRefPubMed Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. 2000, 164 (7): 3596-3599.CrossRefPubMed
23.
go back to reference Grohmann U, Bianchi R, Orabona C, Fallarino F, Vacca C, Micheletti A, Fioretti MC, Puccetti P: Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol. 2003, 171 (5): 2581-2587.CrossRefPubMed Grohmann U, Bianchi R, Orabona C, Fallarino F, Vacca C, Micheletti A, Fioretti MC, Puccetti P: Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol. 2003, 171 (5): 2581-2587.CrossRefPubMed
24.
go back to reference Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, et al: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat immunol. 2002, 3 (11): 1097-1101. 10.1038/ni846.CrossRefPubMed Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, et al: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat immunol. 2002, 3 (11): 1097-1101. 10.1038/ni846.CrossRefPubMed
25.
go back to reference Tang KF, Tan SY, Chan SH, Chong SM, Loh KS, Tan LK, Hu H: A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum pathol. 2001, 32 (1): 42-49. 10.1053/hupa.2001.20886.CrossRefPubMed Tang KF, Tan SY, Chan SH, Chong SM, Loh KS, Tan LK, Hu H: A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum pathol. 2001, 32 (1): 42-49. 10.1053/hupa.2001.20886.CrossRefPubMed
26.
go back to reference Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G: Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J exp med. 2002, 196 (4): 447-457. 10.1084/jem.20020052.CrossRefPubMedPubMedCentral Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G: Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J exp med. 2002, 196 (4): 447-457. 10.1084/jem.20020052.CrossRefPubMedPubMedCentral
27.
go back to reference Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM: Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J neuroimmunol. 2002, 129 (1-2): 186-196. 10.1016/S0165-5728(02)00176-5.CrossRefPubMed Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM: Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J neuroimmunol. 2002, 129 (1-2): 186-196. 10.1016/S0165-5728(02)00176-5.CrossRefPubMed
28.
go back to reference Hu H, Tang KF, Chua YN, Lu J, Feng P, Chew CT, Chan SH: Expression of interleukin-18 by nasopharyngeal carcinoma cells: a factor that possibly initiates the massive leukocyte infiltration. Hum pathol. 2004, 35 (6): 722-728. 10.1016/j.humpath.2004.01.026.CrossRefPubMed Hu H, Tang KF, Chua YN, Lu J, Feng P, Chew CT, Chan SH: Expression of interleukin-18 by nasopharyngeal carcinoma cells: a factor that possibly initiates the massive leukocyte infiltration. Hum pathol. 2004, 35 (6): 722-728. 10.1016/j.humpath.2004.01.026.CrossRefPubMed
29.
go back to reference Tang KF, Chan SH, Loh KS, Chong SM, Wang D, Yeoh KH, Hu H: Increased production of interferon-gamma by tumour infiltrating T lymphocytes in nasopharyngeal carcinoma: indicative of an activated status. Cancer lett. 1999, 140 (1-2): 93-98. 10.1016/S0304-3835(99)00056-7.CrossRefPubMed Tang KF, Chan SH, Loh KS, Chong SM, Wang D, Yeoh KH, Hu H: Increased production of interferon-gamma by tumour infiltrating T lymphocytes in nasopharyngeal carcinoma: indicative of an activated status. Cancer lett. 1999, 140 (1-2): 93-98. 10.1016/S0304-3835(99)00056-7.CrossRefPubMed
30.
go back to reference Faivre S, Janot F, Armand JP: Optimal management of nasopharyngeal carcinoma. Curr opin oncol. 2004, 16 (3): 231-235. 10.1097/00001622-200405000-00007.CrossRefPubMed Faivre S, Janot F, Armand JP: Optimal management of nasopharyngeal carcinoma. Curr opin oncol. 2004, 16 (3): 231-235. 10.1097/00001622-200405000-00007.CrossRefPubMed
31.
go back to reference Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S: Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer. 2007, 120 (11): 2401-2410. 10.1002/ijc.22334.CrossRefPubMed Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S: Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer. 2007, 120 (11): 2401-2410. 10.1002/ijc.22334.CrossRefPubMed
32.
go back to reference Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, et al: Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res. 2006, 12 (19): 5726-5732. 10.1158/1078-0432.CCR-06-0571.CrossRefPubMed Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, et al: Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res. 2006, 12 (19): 5726-5732. 10.1158/1078-0432.CCR-06-0571.CrossRefPubMed
33.
go back to reference Zanussi S, Vaccher E, Caffau C, Pratesi C, Crepaldi C, Bortolin MT, Tedeschi R, Politi D, Barzan L, Tirelli U, et al: Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother. 2003, 52 (1): 28-32.PubMed Zanussi S, Vaccher E, Caffau C, Pratesi C, Crepaldi C, Bortolin MT, Tedeschi R, Politi D, Barzan L, Tirelli U, et al: Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother. 2003, 52 (1): 28-32.PubMed
34.
go back to reference Munn DH, Sharma MD, Mellor AL: Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004, 172 (7): 4100-4110.CrossRefPubMed Munn DH, Sharma MD, Mellor AL: Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004, 172 (7): 4100-4110.CrossRefPubMed
35.
go back to reference Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, Freewan M, Stocker R: Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem. 2007, 282 (33): 23778-23787. 10.1074/jbc.M700669200.CrossRefPubMed Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, Freewan M, Stocker R: Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem. 2007, 282 (33): 23778-23787. 10.1074/jbc.M700669200.CrossRefPubMed
36.
go back to reference Logan GJ, Smyth CM, Earl JW, Zaikina I, Rowe PB, Smythe JA, Alexander IE: HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity. Immunology. 2002, 105 (4): 478-487. 10.1046/j.1365-2567.2002.01390.x.CrossRefPubMedPubMedCentral Logan GJ, Smyth CM, Earl JW, Zaikina I, Rowe PB, Smythe JA, Alexander IE: HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity. Immunology. 2002, 105 (4): 478-487. 10.1046/j.1365-2567.2002.01390.x.CrossRefPubMedPubMedCentral
37.
go back to reference Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH: Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002, 168 (8): 3771-3776.CrossRefPubMed Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH: Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002, 168 (8): 3771-3776.CrossRefPubMed
38.
go back to reference Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC, Kim TG: Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol. 2006, 83 (1): 66-73. 10.1532/IJH97.A30505.CrossRefPubMed Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC, Kim TG: Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol. 2006, 83 (1): 66-73. 10.1532/IJH97.A30505.CrossRefPubMed
39.
go back to reference Meij P, Bloemena E, Palmen N, Brink A, Vervoort MB, Meijer CJ, Middeldorp JM: Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines. Cell Immunol. 2001, 208 (1): 25-33. 10.1006/cimm.2001.1760.CrossRefPubMed Meij P, Bloemena E, Palmen N, Brink A, Vervoort MB, Meijer CJ, Middeldorp JM: Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines. Cell Immunol. 2001, 208 (1): 25-33. 10.1006/cimm.2001.1760.CrossRefPubMed
40.
go back to reference Encke J, Findeklee J, Geib J, Pfaff E, Stremmel W: Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol. 2005, 142 (2): 362-369. 10.1111/j.1365-2249.2005.02919.x.CrossRefPubMedPubMedCentral Encke J, Findeklee J, Geib J, Pfaff E, Stremmel W: Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol. 2005, 142 (2): 362-369. 10.1111/j.1365-2249.2005.02919.x.CrossRefPubMedPubMedCentral
41.
go back to reference Ou X, Cai S, Liu P, Zeng J, He Y, Wu X, Du J: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol. 2008, 134 (5): 525-533. 10.1007/s00432-007-0315-9.CrossRefPubMed Ou X, Cai S, Liu P, Zeng J, He Y, Wu X, Du J: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol. 2008, 134 (5): 525-533. 10.1007/s00432-007-0315-9.CrossRefPubMed
42.
go back to reference Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J exp med. 2002, 196 (4): 459-468. 10.1084/jem.20020121.CrossRefPubMedPubMedCentral Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB: Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J exp med. 2002, 196 (4): 459-468. 10.1084/jem.20020121.CrossRefPubMedPubMedCentral
43.
go back to reference Farhat K, Hassen E, Gabbouj S, Bouaouina N, Chouchane L: Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet. 2008, 35 (3): 197-205. 10.1111/j.1744-313X.2008.00752.x.CrossRefPubMed Farhat K, Hassen E, Gabbouj S, Bouaouina N, Chouchane L: Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet. 2008, 35 (3): 197-205. 10.1111/j.1744-313X.2008.00752.x.CrossRefPubMed
44.
go back to reference Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC: Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007, 67 (15): 7082-7087. 10.1158/0008-5472.CAN-07-1872.CrossRefPubMed Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC: Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007, 67 (15): 7082-7087. 10.1158/0008-5472.CAN-07-1872.CrossRefPubMed
Metadata
Title
Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes
Authors
Peng Liu
Bai-Lu Xie
Shao-Hui Cai
Yun-Wen He
Ge Zhang
Yan-Mei Yi
Jun Du
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-416

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine